# Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

> **NCT04421469** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Triprilimab(JS001)

## Key facts

- **NCT ID:** NCT04421469
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-15
- **Primary completion:** 2023-04-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421469, "Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04421469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*